You are about to leave this website for another external website. Gamida Cell has no responsibility for the content of such other sites and is not liable for any damages or injury arising from that content. Any links to other sites are provided merely as a convenience to the users of this website.
News & Events
News
-
3Dec. 2018
-
28Nov. 2018
-
1Nov. 2018Gamida Cell Announces New Translational Data for NiCord® to be Presented at ASH 2018 Annual Meeting
BOSTON, Mass., November 1, 2018 – Gamida Cell Ltd. (Nasdaq: GMDA), a leading cellular and immune therapeutics company, today announced that new translational data for NiCord®, an investigational cell therapy in Phase 3 clinical development for allogeneic stem cell, or bone marrow, transplant, will be presented at the American Society of Hematology (ASH) 2018 Annual […]
-
26Oct. 2018Gamida Cell Announces Pricing of Initial Public Offering
BOSTON, Mass., October 26, 2018 – Gamida Cell Ltd., a leading cellular and immune therapeutics company, today announced the pricing of its initial public offering of 6,250,000 ordinary shares at a public offering price of $8.00 per share for aggregate gross proceeds of $50.0 million. All of the shares in the offering are being offered […]
-
18Sep. 2018Gamida Cell Strengthens Its Board of Directors with Appointment of Robert Blum as Chairman
BOSTON, Mass., September 18, 2018 – Gamida Cell, a leading cellular and immune therapeutics company, today announced the appointment of Robert Blum, president and chief executive officer of Cytokinetics, Inc., as chairman of Gamida Cell’s board of directors. Julian Adams, Ph.D., Gamida Cell’s chief executive officer and previous chairman, will remain on the company’s board […]
-
6Aug. 2018Gamida Cell Expands its Leadership Team with the Appointment of Jaren Madden as Vice President, Investor Relations and Corporate Communications
BOSTON, Mass., August 6, 2018 – Gamida Cell, a leading cellular and immune therapeutics company, today announced the appointment of Jaren Madden as vice president, investor relations and corporate communications. Ms. Madden brings nearly 20 years of strategic communications experience to this new role at Gamida Cell, and will be responsible for the company’s engagement […]
-
23Jul. 2018Gamida Cell Expands Leadership Team with Appointments of Tzvi Palash as Chief Operating Officer and John Schick as Vice President of Market Access
CAMBRIDGE, Mass., July 23, 2018 – Gamida Cell, a leading cellular and immune therapeutics company, today announced the appointments of Tzvi Palash as chief operating officer (COO) and John D. Schick as vice president, market access. Mr. Palash brings over 30 years of expertise in commercial operations in the healthcare industry to this new role […]
-
18Jun. 2018Gamida Cell to Present Preliminary Data from Ongoing Phase I NAM-NK Study at AACR International Meeting on Advances in Malignant Lymphoma
CAMBRIDGE, Mass., June 18, 2018 – Gamida Cell, a leading cellular and immune therapeutics company, today announced that preliminary data from an ongoing phase I study from the nicotinamide-based natural killer cell expansion, or NAM-NK, program will be presented during the Inaugural AACR International Meeting on Advances in Malignant Lymphoma, held June 22 – 26 […]
-
30Apr. 2018Gamida Cell to Present NiCord® Data at ISCT 2018 Annual Meeting
CAMBRIDGE, Mass., April 30, 2018 – Gamida Cell, a leading cellular and immune therapeutics company, today announced that data from the company’s NiCord program will be presented during the International Society for Cellular Therapy (ISCT) Annual Meeting, held May 2-5 in Montreal. Jaap Jan Boelens, M.D., Ph.D., clinical study investigator and pediatric oncologist/immunologist at the […]
-
26Apr. 2018Gamida Cell Strengthens Leadership Team with Appointments of Josh Hamermesh as Chief Business Officer and Paul Nee as Vice President of Marketing
CAMBRIDGE, Mass., April 26, 2018 – Gamida Cell, a leading cellular and immune therapeutics company, today announced the appointments of Josh Hamermesh as chief business officer and Paul Nee as vice president, marketing. Mr. Hamermesh will lead the business operations and corporate development strategies for the company. Mr. Hamermesh joins Gamida Cell from Locust Walk […]
-
19Mar. 2018Gamida Cell to Present Immune Reconstitution Data for its NiCord® Program at the 2018 EBMT Annual Meeting
NiCord recipients demonstrated rapid and robust immune reconstitution following transplantation CAMBRIDGE, Mass., March 19, 2018 – Gamida Cell, a leading cellular and immune therapeutics company, today announced that new data on immune reconstitution (IR) from its phase I/II study of NiCord in high-risk hematologic malignancies will be presented during the 44th Annual Meeting of the […]
-
16Mar. 2018Gamida Cell to Present at Upcoming Investor Conferences
CAMBRIDGE, Mass., March 16, 2018 – Gamida Cell, a leading cellular and immune therapeutics company, today announced that the company will participate in two upcoming investor conferences: Julian Adams, Ph.D., chairman and chief executive officer, will share a company overview at the Oppenheimer 28th Annual Healthcare Conference at 2:45 p.m. on Wednesday, March 21, 2018 […]
-
15Mar. 2018Gamida Cell Appoints Shai Lankry as Chief Financial Officer
CAMBRIDGE, Mass., March 15, 2018 – Gamida Cell, a leading cellular and immune therapeutics company, today announced the appointment of Shai Lankry, CPA, MBA, as chief financial officer (CFO). Mr. Lankry brings more than a decade of senior management experience in finance at both public and private companies to his new role as CFO of […]
-
20Feb. 2018Gamida Cell to Present Data from NiCord® Programs at the 2018 BMT Tandem Meetings
– NiCord demonstrated rapid and durable engraftment in patients with high-risk hematologic malignancies – – 13 patients with sickle cell disease transplanted with NiCord and engrafted at median seven days – CAMBRIDGE, Mass., February 20, 2018 – Gamida Cell, a leading cellular and immune therapeutics company, today announced two presentations from its NiCord programs in […]
-
16Jan. 2018Gamida Cell Announces Initiation of a Phase I Study of NAM-NK Cells Immunotherapy Program for Non-Hodgkin Lymphoma and Multiple Myeloma
CAMBRIDGE, Mass., January 16, 2018 – Gamida Cell, a leading cellular and immune therapeutics company, today announced the initiation of a phase I study evaluating its proprietary NAM-expanded natural killer cells (NAM-NK Cells) in patients with relapsed or refractory CD20+ non-Hodgkin lymphoma (NHL) and multiple myeloma. “There is significant need for novel therapeutic approaches for […]
-
11Dec. 2017Gamida Cell Presents Data from Two Key Development Programs at the 2017 ASH Annual Meeting
— Final results from the company’s phase I/II study of NiCord® demonstrate important potential as a universal transplantation solution for patients with high-risk blood cancers — — Preclinical study of NAM-NK Cells supports utility as an immunotherapeutic modality for treating cancer — JERUSALEM and CAMBRIDGE, Mass., December 11, 2017 – Gamida Cell, a leading cellular […]
-
20Nov. 2017Gamida Cell Appoints Julian Adams, Ph.D., Chairman and Chief Executive Officer
Biotech leader to further advance promising pipeline, including breakthrough therapy, NiCord®, in phase 3 development as a universal bone marrow transplant solution JERUSALEM, Israel and CAMBRIDGE, Mass., November 20, 2017 – Gamida Cell, a leading cellular and immune therapeutics company, today announced the appointment of Julian Adams, Ph.D., as chairman and chief executive officer. Dr. […]
-
1Nov. 2017Gamida Cell to Present New Data from Key Programs at 2017 ASH Annual Meeting
Phase 2 NiCord Data in Allogeneic Bone Marrow Transplant and Preclinical Data for NK Cells to be Presented in Oral Presentations JERUSALEM, Israel, November 1, 2017 – Gamida Cell, a leading cellular and immune therapeutics company, today announced that two oral presentations on new data from the company’s pipeline programs will be presented during the […]
-
26Sep. 2017Gamida Cell World Cord Blood Day Conference, November 15, 2017
Advisory Event: Gamida Cell World Cord Blood Day Conference This conference will present the newest research in cord blood expansion for cellular and immune treatment of cancer and orphan genetic diseases. Date: November 15, 2017 Location: Gamida Cell, Beit Ofer, 5 Nahum Hafzadi Street, Jerusalem, ISRAEL. This event is open to the general public. Contact: kelly@gamida-cell.com […]
-
21Aug. 2017Gamida Cell Announces First Patient Transplanted in Phase 1/2 Study of CordIn for Severe Aplastic Anemia and Hypoplastic MDS
This investigator initiated study is being conducted in collaboration with the U.S. National Heart, Lung and Blood Institute (NHLBI) Jerusalem, Israel, August 21, 2017 — The first subject has been transplanted in an investigator-initiated study of Cordin™ for patients with severe aplastic anemia (AA) or hypoplastic myelodysplastic syndrome (MDS) who have no available matched donor. […]
-
20Jul. 2017Gamida Cell Announces $3.5 Million Grant from the Israeli Government
Non-dilutive funding follows the recent closing of a $40 million round Combined financing will support further development and commercialization of NiCord®, a breakthrough designation product for blood cancers Jerusalem, Israel, July 20, 2017 — Gamida Cell, a leader in cellular and immune therapies for the treatment of cancer and orphan genetic diseases, announced today that […]
-
10Jul. 2017Gamida Cell Inc. Names Ronit Simantov, M.D. as Chief Medical Officer
Dr. Simantov brings to the company extensive medical experience in late stage development and commercialization of cancer treatments Jerusalem, Israel and New York, New York, July 10, 2017 — Gamida Cell, a leader in cellular and immune therapies for the treatment of cancer and orphan genetic diseases, announced today that Ronit Simantov, M.D. will join […]
-
19Jun. 2017Gamida Cell Announces $40 Million Private Financing
Financing provides strong base to complete Phase 3 clinical trial and commercialization of lead product candidate NiCord® for blood cancers Jerusalem, Israel, June 19, 2017 — Gamida Cell Ltd., a leader in cellular and immune therapies for the treatment of cancer and orphan genetic diseases, today announced the signing of a $40 million financing to […]